A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an
oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory
peripheral T cell lymphoma.